AlphAIAlphAI — Financial news for AI agents
Capital.comMAR 312 min read$SPOK

Spok Holdings Inc (SPOK) Stock Price Quote Today & Current Price Chart | Capital.com Australia

This page provides current stock price information and trading conditions for Spok Holdings Inc (SPOK) on Capital.com Australia, presented as a CFD. It details key statistics like previous close, open price, 1-year change, and day's range. The article also includes information about CFD trading risks, margin details, and recent market analysis articles relevant to the broader market.

Original reporting
Capital.com
Published Mar 31, 2026, 4:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 31, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$SPOK
Neutral
medium confidence
Mentioned
$SPOK
Relevance
6/10
AlphAI data visualization · based on Capital.com
Decision brief

The 30-second read

$SPOKNeutralLow
01

Why it matters

Given the lack of significant news or catalysts, the impact on SPOK's stock price is expected to be limited in the short term.

02

Market read

The news is primarily relevant for traders interested in CFD trading of SPOK, with limited influence on the underlying stock or broader markets.

03

What to watch

Potential upcoming earnings reports or sector developments could influence future price movements, which are not covered in this article.

Relevance 6/10Timing: short-term

Background

This article provides a snapshot of SPOK's current trading status within the CFD market, emphasizing recent statistics and risk disclosures.

Company-level read

Ticker impact

$SPOKNeutralMedium confidence
Context

The news provides current stock price information and recent market analysis for Spok Holdings Inc (SPOK), but the relevance score is low (0.0453), indicating limited immediate trading impact.

Expected impact

Likely minimal short-term price change; expected to remain within recent trading range.

Evidence & confidence

The sentiment is neutral, and the article lacks new developments or catalysts; thus, the impact on price is expected to be negligible.

Market effects

Sector

Limited sector impact due to the company's specific focus and the absence of sector-wide news.

Regional

Minimal regional market influence; the article pertains to Australian CFD trading of a US company.

Global

Low global market relevance given the neutral sentiment and lack of significant news.

Counterpoint

What could challenge this read

If new information emerges, SPOK could experience increased volatility; traders should stay alert for updates.

Key entities

  • Company
    Spok Holdings Inc

    A provider of healthcare communication solutions.

Read at source← All news

Related articles

JUL 29
$SPOKMed

Spok Reports Second Quarter 2026 Results

Spok Holdings, Inc (SPOK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE CONTACT: Al Galgano 952-224-6096 al.galgano@spok.com Spok Reports Second Quarter 2026 Results Company Generates $4.1 Million of Net Income and $9.1 Million of Adjusted EBITDA Software Operations Bookings Up Nearly 92% From the Prior Quarter Executes Agre

SEC EDGAR 8-K6 min
OCT 28
$FWRDMed

Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship

FORWARD AIR CORP (FWRD) filed an SEC Form 8-K — Other Events. Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship 2026 to 2028 Forecasted Annual Revenue from Customer Expected to Exceed 2025 Revenue Driven by Growth in Retained Services DALLAS – October 28, 2026 – F

SEC EDGAR 8-K4 min
OCT 28
$PYPDMedAI 8/10

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

investing.com2 min
OCT 28
$KTOSMed

Kratos wins $33.6 million NASA power system contract

Kratos Defense & Security Solutions (KTOS) won a $33.6M contract from NASA to design and build a power system for the Space Reactor-1 Freedom spacecraft, launching in 2028. Kratos will work as a subcontractor to Sierra Lobo under NASA’s SpaceDOC III contract, providing a power conversion system for the mission to Mars. The spacecraft aims to demonstrate nuclear electric propulsion technology. According to the company, the contract is a significant milestone in advancing space nuclear propulsion.

investing.com3 min